Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B

Yvonne Brennan, Jennifer Curnow, Emmanuel J Favaloro

Research output: Contribution to journalReview articlepeer-review


INTRODUCTION: Current treatment for hemophilia B involves replacing the missing coagulation factor IX (FIX) with either plasma-derived or recombinant (r) FIX. Trenonacog alfa is the third normal half-life rFIX that has been granted FDA approval.

Area covered: In this review, the authors examine trenonacog alfa for the treatment of hemophilia B including prophylaxis, on-demand and perioperative hemostasis. They compare the PK profile to nonacog alfa and evaluate the drug's efficacy and safety from published studies.

Expert opinion: Trenonacog alfa appears to be an effective and safe treatment option for patients with hemophilia B with a PK profile similar to that of nonacog alfa. Despite the advent of extended half-life rFIX and other novel therapeutic approaches, normal half-life rFIX products, including trenonacog alfa, are likely to continue to have a place in hemophilia B treatment for at least the immediate future while the new landscape takes shape, particularly in countries that cannot afford the newer treatments.

Original languageEnglish
Pages (from-to)95-100
Number of pages6
JournalExpert Opinion on Biological Therapy
Issue number1
Early online date26 Nov 2017
Publication statusPublished - Jan 2018


Dive into the research topics of 'Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B'. Together they form a unique fingerprint.

Cite this